1Ogawa H,Kim-Mitsuyama S,Jinnouchi T,et al.Rationale,design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized(OSCAR)study:a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker(ARB)monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk bypertensive patients(ClinicalTrials.gov no.NCT00134160)[J].Hypertens Res,2009,32:575-580.
2Matsushita K,Muramatsu T,Kondo T,et al.Rationale and design of the NAGOYA HEART Study:comparison between valsartan and am-lodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance[J].J Cardio1,2010,56:111-117.
3Mochizuki S,Dahlof B,Shimizu M,et al.Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study):a randomised,open-label,blinded endpoint morbidity-mortality study[J] ,Lancet,2007,369:1431-1439.
4Sawada T,Yamada H,Dah1Gf B,et al.Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks:KYOTO HEART Study[J].Eur Heart J,2009,30:2461-2469.
5Ogihara T,Nakao K,Fukui T,et al.Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks:candesartan antihypertensive survival evaluation in Japan trial[J].Hypertension,2008,51:393-398.
6Wang JG,Karin K,Lau T,et al.Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians:A scientific statement from the Asian Pacific Heart Association[J].Hypertens Res,2011,34:423-430.
7Wang JG,Li Y,Franklin SS,et al.Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers:a quantitative overview[J].Hypertension,2007,50:181-188.
9Liu L,Wang JG,Gong L,et al.Comparison of active treatment and placebo for older Chinese patients with isolated systolic hypertension Dl.J Hypertens,1998,16:1823-1829.
10Wang JG,Staessen JA,Gong L,et al.Chinese trial on isolated systolic hypertension in the el-derly[J].Arch Intern Med,2000,160:211-220.
3Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension : analysis of worldwide data. Lancet, 2005,365:217- 223.
4Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens, 1998,16 : 1823-1829.
5Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens, 1996,14 : 1237-1245.
6Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypcrtens, 2005,23 : 2157- 2172.
7Furukawa T, Yamakawa T, Midera T, et al. Selectivities of dihydropyridine derivatives in blocking Ca(2 + ) channel subtypes expressed in Xenopus oocytes. J Pharmaeol Exp Ther, 1999,291 : 464-473.
8Hayashi K, Wakino S, Sugano N, et al. Ca2 + channel subtypes and pharmacology in the kidney. Circ Res, 2007,100:342-353.
9Yamamoto T, Niwa S, Ohno S, et al. Structure-activity relationship study of 1, 4-dihydropyridine derivatives blocking N-type calcium channels. Bioorg Med Chem Lett, 2006,16 : 798- 802.
10Kimura K, Suzuki N, Ohba S, et al. Effect of amlodipine, a calcium channel blocker, on rat renal arterioles, current therapeuticresearch? 1997, Curr THERAPEUTIC Resarch,58:375- 380.
1Hansen TW,Thijs L,Li Y,et al.On behalf of the international database on ambulatory blood pressure in relation to cardiovascular outcomes (IDACO) investigators.Prognostic value of short-term blood pressure variability over 24 hours in 8937 subjects from 11 populations[J].Hypertension,2010,55(4):1049-1057.
2Elliott HL,Meredith PA.Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade:further analysis of the ‘ACTION’ database in patients with angina[J].J Hum Hypertens,2011,25 (1):63-70.
